BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2,103.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,278,555 shares of the biotechnology company’s stock after buying an additional 4,084,403 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 2.04% of BioCryst Pharmaceuticals worth $38,336,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Headlands Technologies LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at approximately $32,000. New Age Alpha Advisors LLC purchased a new position in BioCryst Pharmaceuticals during the 1st quarter worth approximately $62,000. Family Legacy Financial Solutions LLC acquired a new stake in BioCryst Pharmaceuticals during the 2nd quarter valued at $72,000. Inceptionr LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the second quarter valued at $107,000. Finally, Choreo LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the second quarter worth $121,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $7.59 on Friday. The firm has a market cap of $1.60 billion, a PE ratio of -151.80 and a beta of 0.91. The firm’s 50 day moving average price is $7.12 and its 200 day moving average price is $8.35. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). The business had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The business’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.07) EPS. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BCRX. Cantor Fitzgerald lifted their price target on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. Weiss Ratings restated a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Barclays dropped their target price on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 4th. JMP Securities increased their price target on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research report on Wednesday, October 15th. Finally, Citizens Jmp decreased their price target on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a report on Wednesday, November 5th. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 91,004 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $7.10, for a total transaction of $646,128.40. Following the transaction, the insider directly owned 416,152 shares of the company’s stock, valued at $2,954,679.20. This represents a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold 161,680 shares of company stock worth $1,164,401 over the last 90 days. Corporate insiders own 5.10% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.